Italia markets open in 8 hours 30 minutes

Mauna Kea Technologies SA (0P5I.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
0,6270+0,0210 (+3,47%)
Alla chiusura: 06:03PM BST
Schermo intero
Chiusura precedente0,6060
Aperto0,6270
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno0,6270 - 0,6270
Intervallo di 52 settimane0,6270 - 0,6270
Volume447
Media VolumeN/D
Capitalizzazione192.470
Beta (5 anni mensile)1,86
Rapporto PE (ttm)N/D
EPS (ttm)-0,3530
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Recce Pharmaceuticals Announces Phase I Clinical Trial of RECCE® 327 Advances to High Dosing Level

    Dose increase of R327 Dose increase of R327 Highlights: 36 subjects successfully dosed in Phase I intravenous (IV) clinical trial of RECCE® 327 (R327) – demonstrating good safety and tolerability at 1,000mg Independent Safety Committee affirms ‘low-dose’ cohort clinical trial complete, endpoints achieved – recommends ‘high dose’ cohort dosing to beginCommittee clears cohort five (R327 – 2,000mg IV) dosing – subjects recruited and dosing underway SYDNEY, Australia, April 13, 2022 (GLOBE NEWSWIRE)

  • GlobeNewswire

    Recce Pharmaceuticals Announces Anti-Viral Patent Granted in Hong Kong for RECCE® Anti-Infectives

    SYDNEY, Australia, April 12, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Intellectual Property Department of the Hong Kong Special Administrative Region has granted patent family three, “Anti-Virus Agent and Method for Treatment of Viral Infection,” furthering marketing and manufacturing exclusivity to February 2037. “As we continue to build our patent portfolio in key geogr